Share Twitter LinkedIn Facebook Email David I. Quinn, MD, discusses whether the convenience factor of oral TKIs enters into the decision-making process when treating advanced renal cell carcinoma (RCC) patients
VIDEO: FDA Approves Atezolizumab / Tecentriq Hybreza For Subcutaneous PD-(L)1 Cancer Immunotherapy in NSCLC Kidney 4 Mins Read
Nivolumab Combo Phase 3 TiNivo 2 Results + Tivozanib in RCC Presented at ESMO 2024: AVEO Kidney 4 Mins Read
Impact of Latino Ethnicity on Gut Microbiome in mRCC: ASCO 2024 Study – Regina Barragan-Carillo, Phd – City of Hope ASCO Annual Meeting 2 Mins Read
